Amneal Pharmaceuticals reported first‑quarter 2026 results on April 22, 2026, posting revenue of $723 million and a GAAP earnings per share of $0.19. Adjusted earnings per share were $0.27, a beat of $0.10–$0.12 over the consensus range of $0.15–$0.17 and a revenue beat of $8 million over the $715 million estimate.
Revenue grew 4% year‑over‑year, driven by a higher mix of complex generics and specialty products. Gross margin expanded to 44.3%, reflecting pricing power and disciplined cost management. The mix shift toward higher‑margin segments also contributed to the improved operating leverage that underpinned the adjusted EPS beat.
The adjusted EPS beat was largely a result of stronger operating performance and lower cost of goods sold relative to revenue growth. Amneal’s operating income rose in line with revenue, while the company maintained tight control over manufacturing and supply‑chain costs.
Management highlighted that the mix shift and robust demand in specialty segments support the company’s confidence in its growth trajectory. Accordingly, Amneal raised its full‑year 2026 guidance to adjusted EPS of $0.95–$1.05 and revenue of $3.05–$3.15 billion, up from the prior guidance range of $0.93–$1.03 EPS.
Analysts noted the earnings beat and guidance raise as evidence of strong execution and confidence in the biosimilars pipeline, especially following the acquisition of Kashiv BioSciences for up to $1.1 billion. The deal is expected to close in the second half of 2026 and positions Amneal as a fully integrated global biosimilars leader.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.